Summary of Key Points Core Viewpoint - Hendi Pharmaceutical (301211.SZ) announced plans for significant share reductions by major shareholders, indicating potential changes in ownership structure and market sentiment towards the company [1] Group 1: Shareholder Reductions - Shareholder Ningkang Enterprise Management Center (Limited Partnership) plans to reduce its holdings by up to 4,176,000 shares, representing 1% of the total share capital, within three months after the announcement [1] - Shareholder Beikang Enterprise Management Center (Limited Partnership) intends to reduce its holdings by up to 1,392,000 shares, accounting for 0.33% of the total share capital, within the same timeframe [1] - Shareholder Lei Xiaoyan plans to reduce her holdings by up to 4,176,000 shares, also representing 1% of the total share capital, within three months after three trading days from the announcement [1]

Core Viewpoint - Hendi Pharmaceutical Co., Ltd. announced a share reduction plan involving three shareholders, aiming to reduce a total of up to 9.744 million shares, representing 2.33% of the company's total share capital [1][2]. Share Reduction Plan Details - The share reduction plan involves three shareholders: Jingmen Ningkang Enterprise Management Center (Limited Partnership), Jingmen Beikang Enterprise Management Center (Limited Partnership), and Lei Xiaoyan, all citing "personal financial planning" as the reason for the reduction [2]. - The specific reduction plans are as follows: - Ningkang Enterprise plans to reduce up to 4.176 million shares (1% of total shares) from December 4, 2025, to March 3, 2026 [2]. - Beikang Enterprise plans to reduce up to 1.392 million shares (0.33% of total shares) during the same period [2]. - Lei Xiaoyan plans to reduce up to 4.176 million shares (1% of total shares) from November 18, 2025, to February 17, 2026 [2]. Shareholder Basic Information - The shareholdings of the three shareholders are as follows: - Ningkang Enterprise holds 23.49 million shares (5.63% of total shares) [3]. - Beikang Enterprise holds 7.83 million shares (1.88% of total shares) [3]. - Lei Xiaoyan holds 15.66 million shares (3.75% of total shares) [3]. Compliance and Commitment Fulfillment - The share reduction plan complies with previous commitments made by the shareholders, who had locked their shares for 36 months post-IPO, with an automatic extension if the stock price fell below the IPO price within six months [3][4]. - As of the announcement date, all three shareholders have adhered to their share lock-up and reduction intentions without any violations [4].

Group 1 - The core point of the article is that Hendi Pharmaceutical (301211) announced plans for significant share reductions by several shareholders [1] Group 2 - Shareholder Jingmen Ningkang Enterprise Management Center (Limited Partnership), holding 5.63% of shares, plans to reduce holdings by up to 4.176 million shares, representing 1% of the total share capital [1] - Shareholder Jingmen Beikang Enterprise Management Center (Limited Partnership), holding 1.88% of shares, plans to reduce holdings by up to 1.392 million shares, representing 0.33% of the total share capital [1] - Shareholder Lei Xiaoyan, holding 3.75% of shares, plans to reduce holdings by up to 4.176 million shares, also representing 1% of the total share capital [1]

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) announced plans for significant share reductions by major shareholders, indicating potential changes in ownership structure and market sentiment [1] Shareholder Reduction Plans - Shareholder Jingmen Ningkang Enterprise Management Center (Limited Partnership) plans to reduce its holdings by up to 4.176 million shares, representing 1% of the company's total share capital, within three months after the announcement [1] - Shareholder Jingmen Beikang Enterprise Management Center (Limited Partnership) intends to reduce its holdings by up to 1.392 million shares, accounting for 0.33% of the company's total share capital, within the same timeframe [1] - Shareholder Lei Xiaoyan plans to reduce her holdings by up to 4.176 million shares, also representing 1% of the company's total share capital, within three months following the announcement [1]

Group 1 - The company Hendy Pharmaceutical (301211.SZ) announced that shareholder Jingmen Ningkang Enterprise Management Center (Limited Partnership) plans to reduce its holdings by up to 4.176 million shares, accounting for 1% of the total share capital, within three months after fifteen trading days from the announcement date [1] - Shareholder Jingmen Beikang Enterprise Management Center (Limited Partnership) intends to reduce its holdings by up to 1.392 million shares, representing 0.33% of the total share capital, within the same timeframe [1] - Shareholder Lei Xiaoyan plans to reduce her holdings by up to 4.176 million shares, also accounting for 1% of the total share capital, within three months after three trading days from the announcement date [1]

Group 1 - The company Hendi Pharmaceutical announced that shareholder Ningkang Enterprise Management holds 23.49 million shares, accounting for 5.63%, and plans to reduce its holdings by up to 4.176 million shares, representing 1%, through block trading or centralized bidding from December 4, 2025, to March 3, 2026 [1] - Shareholder Beikang Enterprise Management, holding 7.83 million shares, which is 1.88%, intends to reduce its stake by up to 1.392 million shares, equivalent to 0.33%, during the same period [1] - Shareholder Lei Xiaoyan, with 15.66 million shares, accounting for 3.75%, plans to reduce holdings by up to 4.176 million shares, representing 1%, from November 18, 2025, to February 17, 2026 [1]

3、持有公司股份 15,660,000 股（占公司总股本比例 3.75%）的股东雷小艳 计划在本公告披露之日起三个交易日后的三个月内以大宗交易方式或集中竞价 交易方式合计减持本公司股份不超过 4,176,000 股（占公司总股本比例 1%）。 公司于近日收到宁康企管、倍康企管、雷小艳出具的《关于股份减持计划的 告知函》，现将有关情况公告如下： 一、股东的基本情况 证券代码：301211 证券简称：亨迪药业 公告编号：2025-050 湖北亨迪药业股份有限公司 关于股东减持股份的预披露公告 公司股东荆门市宁康企业管理中心（有限合伙）、荆门市倍康企 业管理中心（有限合伙）、雷小艳保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 1、持有湖北亨迪药业股份有限公司（以下简称"亨迪药业"）股份 23,490,000 股（占公司总股本比例 5.63%）的股东荆门市宁康企业管理中心（有 限合伙）（以下简称"宁康企管"）计划在本公告披露之日起十五个交易日后的 三个月内以大宗交易方式或集中竞价交易方式合计减持本公 ...

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) has registered its ibuprofen raw material for export to Japan, which currently contributes less than 1% of the company's total revenue, thus not significantly impacting its overall performance [1] Group 1 - The company has obtained export qualifications for ibuprofen raw materials to Japan [1] - The revenue from the export business to Japan is currently minimal, accounting for less than 1% of total revenue [1] - The registration in Japan indicates potential for future growth in international markets [1]

Group 1 - The core viewpoint of the news is that Hendi Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with a slight increase in stock price but a significant decline in revenue and net profit [1][2]. Group 2 - On November 11, Hendi Pharmaceutical's stock rose by 2.12%, with a trading volume of 612 million yuan. The financing buy-in amount was 67.87 million yuan, while the financing repayment was 74.80 million yuan, resulting in a net financing buy-in of -6.93 million yuan [1]. - As of November 11, the total margin balance for Hendi Pharmaceutical was 145 million yuan, accounting for 2.19% of its market capitalization, which is above the 60th percentile level over the past year [1]. - The company has not engaged in any short selling activities on November 11, with no shares sold or repaid, indicating a low short selling interest [1]. Group 3 - As of October 31, the number of shareholders for Hendi Pharmaceutical increased by 13.95% to 20,800, while the average circulating shares per person decreased by 12.24% to 20,040 shares [2]. - For the period from January to September 2025, Hendi Pharmaceutical reported a revenue of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% year-on-year [2]. - Since its A-share listing, Hendi Pharmaceutical has distributed a total of 378 million yuan in dividends, with 306 million yuan distributed over the past three years [2]. - As of September 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Hendi Pharmaceutical [2].

Company Summary - Hendi Pharmaceutical (SZ 301211) announced that as of the date of the announcement, Liu Yanchao has pledged approximately 18.79 million shares, accounting for 7.06% of his total holdings. Liu Wenchao has also pledged approximately 18.79 million shares, representing 7.06% of his holdings. Liu Sichao has pledged approximately 18.79 million shares, which is 7.06% of his holdings. Liu Tianchao has pledged approximately 16.12 million shares, making up 6.06% of his holdings [1][1][1] - For the fiscal year 2024, Hendi Pharmaceutical's revenue composition is as follows: raw materials account for 79.88%, formulations account for 19.11%, and others account for 1.01% [1][1][1] - As of the announcement, Hendi Pharmaceutical has a market capitalization of 6.6 billion yuan [1][1][1]